Antibacterial drugs are being elevated to blockbuster status as a new generation of lethal hospital-based superbugs [1] prove resistant to standard therapies, according to a new report from Datamonitor. Community-based infections have always dominated this sector in the past, according to the new report, but drug-resistant superbugs in hospital settings-like MRSA-are changing that. Pfizer's Zyvox and Wyeth's Zosyn have already benefited from the trend and more therapies will be developed as an aging population helps trigger a continued surge in the superbug threat.
- read the UPI article [2] on the Datamonitor report
Related Articles:
Controversial cow drug nears FDA approval. Report [3]
VA program slashes MRSA infection rates. Report [4]
Study: Disinfectant cuts down on MRSA. Report [5]
Links:
[1] http://www.fiercehealthcare.com/story/mrsa-ca-danger-to-healthcare-workers/2006-09-21
[2] http://news.monstersandcritics.com/health/features/article_1274386.php/Superbugs_driving_blockbusters
[3] http://www.fiercebiotech.com/story/controversial-cow-drug-nears-fda-approval/2007-03-05
[4] http://www.fiercehealthcare.com/story/va-program-slashes-mrsa-infection-rates/2007-02-07
[5] http://www.fiercehealthcare.com/story/study-disinfectant-cuts-down-on-msra/2006-10-18